Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jeong-Hoon, Lee, Joon Hyeok, Lim, Young-Suk, Yeon, Jong Eun, Song, Tae-Jin, Yu, Su Jong, Gwak, Geum-Youn, Kim, Kang Mo, Kim, Yoon Jun, Lee, Jae Won, Yoon, Jung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326973/
https://www.ncbi.nlm.nih.gov/pubmed/30232520
http://dx.doi.org/10.1007/s00262-018-2247-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326973/
https://www.ncbi.nlm.nih.gov/pubmed/30232520
http://dx.doi.org/10.1007/s00262-018-2247-4

Ejemplares similares